Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorImmune Oncology Research Institute

About this trial

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of BPDCN

Signed informed consent form for prospective patients

Disqualifiers

None

Trial population

All patients with BPDCN diagnosed since 01.01.2010

Trial design

Design model

Case-only

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Overall survival

Time from diagnosis to death

Time frame
5 years

Secondary outcomes

1

Complete remission rate

The proportion of patients with complete remission

Time frame
5 years
2

Mean duration of the first remission

Time from first remission to disease progression or death

Time frame
5 years
3

Event-free survival

Time from diagnosis to occurrence of a complication

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.